Sanifit to Participate in Upcoming Investor Conferences in December 2020

 

Palma, Spain and San Diego, USA, November 24, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that Joan Perelló, Chief Executive Officer, and Adam Levy, Chief Financial Officer, will participate in two virtual investor conferences in December.

Evercore ISI 3rd Annual HealthCONx Virtual Conference
Management will participate in a fireside chat on Tuesday, December 1 at 9:40 a.m. EST. The team will be available for one-on-one meetings with investors throughout the conference being held December 1-3.

2020 RBC Capital Markets Healthcare Private Company Conference
Management will participate in a fireside chat on Wednesday, December 16 at 11:20 a.m. EST. Throughout the conference, which is being held December 15-16, management will be available to conduct one-on-one meetings with investors.

-ENDS-

About Sanifit
Sanifit is a clinical-stage biopharmaceutical company focused on treatments for vascular calcification disorders. The Company is a spin-off from the University of the Balearic Islands and has offices in Spain and the U.S. Sanifit’s lead asset, SNF472, has successfully completed a Phase 2 proof of concept study in calciphylaxis, and showed a significant reduction in progression of coronary calcification in a Phase 2b study among hemodialysis patients. A Phase 3 pivotal study in calciphylaxis is currently underway and the Company is also pursuing peripheral arterial disease in end-stage kidney disease patients as a second indication for SNF472. For more information, please visit www.sanifit.com.

 

Contacts:

Sanifit:
Joan Perelló, CEO
Adam Levy, CFO
Investor.Relations@sanifit.com

 

Media:
Consilium Strategic Communications
Amber Fennell, Chris Welsh, Sarah Wilson
Tel: +44 (0) 20 3709 5700
Email: sanifit@consilum-comms.com